Evotec AG (NASDAQ:EVTCY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The brokerage presently has a $43.00 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 9.14% from the company’s previous close.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Several other research analysts have also commented on the company. DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research report on Thursday, August 17th. Berenberg Bank lowered Evotec AG from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th.

Evotec AG (EVTCY) traded up 2.60% during trading on Friday, hitting $39.40. The stock had a trading volume of 1,600 shares. Evotec AG has a 52-week low of $9.79 and a 52-week high of $40.23. The company has a 50-day moving average of $32.69 and a 200 day moving average of $26.12. The firm has a market cap of $2.88 billion and a P/E ratio of 67.70.

Evotec AG (NASDAQ:EVTCY) last issued its earnings results on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The firm had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.

TRADEMARK VIOLATION WARNING: “Evotec AG (EVTCY) Stock Rating Upgraded by Zacks Investment Research” was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/03/evotec-ag-evtcy-stock-rating-upgraded-by-zacks-investment-research.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.